Rubric Capital Management (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Rubric Capital Management (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$459M	Sell	15,250,000 -6,105,510	-29%	-$196M	4.87%	5
2025 Q4	$667M	Sell	21,355,510 -3,294,490	-13%	-$81.2M	7.97%	3
2025 Q3	$498M	Sell	24,650,000 -1,350,000	-5%	-$23.7M	5.62%	4
2025 Q2	$436M	Buy	26,000,000 +450,000	+2%	+$7.26M	6.58%	2
2025 Q1	$393M	Buy	25,550,000 +8,550,000	+50%	+$153M	7.04%	2
2024 Q4	$375M	Buy	17,000,000 +994,502	+6%	+$18.1M	4.81%	4
2024 Q3	$288M	Sell	16,005,498 -1,256,243	-7%	-$22M	4.7%	2
2024 Q2	$281M	Sell	17,261,741 -407,847	-2%	-$6.28M	7.35%	1
2024 Q1	$249M	Sell	17,669,588 -557,013	-3%	-$7.02M	7.37%	1
2023 Q4	$190M	Sell	18,226,601 -773,399	-4%	-$7.22M	3.95%	3
2023 Q3	$194M	Buy	19,000,000 +281,638	+2%	+$2.62M	7.27%	2
2023 Q2	$141M	Buy	18,718,362 +14,218,556	+316%	+$115M	6.03%	1
2023 Q1	$39.8M	Buy	+4,499,806	New	+$44.5M	1.03%	24
2019 Q1	–	Sell	-830,000	Closed	-$12.8M	–	72
2018 Q4	$12.8M	Buy	+830,000	New	+$17M	1.58%	24

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rubric Capital Management (New York)'s TEVA Position: Q1 2026 in Review

Rubric Capital Management (New York) reduced its Teva Pharmaceuticals (TEVA) stake by 29% in Q1 2026, selling an estimated $196M and leaving 15,250,000 shares worth $459M. The position accounts for 4.87% of the portfolio, ranked #5.

Rubric Capital Management (New York) first reported a position in TEVA in Q4 2018 and has held it in 14 quarters since. The position peaked at $667M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Rubric Capital Management (New York) held 15,250,000 shares of Teva Pharmaceuticals worth $459M as of Q1 2026.
Rubric Capital Management (New York) sold 6,105,510 Teva Pharmaceuticals shares in Q1 2026, an estimated $196M.
Teva Pharmaceuticals made up 4.87% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #5 holding.
Rubric Capital Management (New York) first reported a position in Teva Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
Rubric Capital Management (New York)'s Teva Pharmaceuticals position peaked at $667M in Q4 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.